Kornimate/medical-research-clean huggingface dataset:
inhibition of the endogenous gip response with a gip receptor antagonist

Conditions: Glucose Metabolism Disorders

Summary: delinieation of gip's effects during an oral glucose tolerance test (ogtt) in humans using gip receptor antagonisation.

aim: to evaluate the role of gipr signalling in postprandial physiology, including bone and glucose homeostasis, using a naturally occurring gip fragment (gip-a), which antagonises the gipr. eighteen healthy men (age 18-70 years, bmi 19-35 kg/m2) with normal kidney and liver parameters and haemoglobin levels and no first-degree relatives with type 2 diabetes will be included in a randomised, double-blinded, placebo-controlled cross-over study. study consists of four study days with concomitant infusions of a) gip-a, b) glp-1 receptor antagonist exendin\[9-39\], c) gip-a + exendin\[9-39\], or d) saline (placebo).

Eligibility criteria:
inclusion criteria: * normal kidney function, liver function and hemoglobin levels. exclusion criteria: * medication, diabetes type 1 or 2, first degree relatives with diabetes type 2

Keywords: gip gip receptor antagonist
circulating tumor dna in surgical lung cancer patients

Conditions: Lung Neoplasms

Summary: conduct a prospective study to detect the change of ctdna of surgical lung cancer patients.

studies have shown the feasibility of detecting mutation status by blood circulating tumor dna (ctdna) in lung cancer patients. the investigators plan to test the blood ctdna in surveillance of surgical lung cancer patients. and evaluate the correlation between ctdna level with tumor relapse or metastasis.

Eligibility criteria:
inclusion criteria: aged 18 to 80 years undergo radical surgery histologically confirmed diagnosis of lung cancer considered primary lung cancer by clinical criteria patients must have given written informed consent exclusion criteria: unable to comply with the study procedure malignant tumor history patients who received any treatment prior to resection unqualified blood samples
gestational weight gain and the electronic medical record

Conditions: Pregnancy; Weight Gain

Summary: less than one third of pregnant women actually achieve the institute of medicine's (iom) recommended weight gain. to date, there are no randomized controlled trials studying the use of the electronic medical record to alert providers to initiate the counseling of patients on the iom gestational weight gain recommendations. in the investigator's planned study intervention, using the epic emr system, an electronic alert (best practice advisory) will appear for providers at each prenatal care visit. this alert will remind providers to counsel patients on the recommendations for gestational weight gain. the control group will receive standard prenatal care, without electronic alerts generated regarding bmi and gestational weight gain. the investigators hypothesize that a higher percentage of patients who receive the intervention will meet the iom guidelines for weight gain.


Eligibility criteria:
inclusion criteria: * pregnant with a single intrauterine gestation * present for new ob visit up to 13 weeks and 6 days gestation exclusion criteria: * they have a multiple gestation pregnancy * they are under the age of 18 * they do not speak english
effect of multimodal analgesia on pain with insertion of levonorgestrel-releasing iud

Conditions: Contraception

Summary: does the addition of cervical lidocaine injections and valium to the current practice result in decreased reported pain with tenaculum placement, iud insertion, and post procedural discomfort? the current practice is ibuprofen alone or no medication.

long acting reversible contraception, including intrauterine devices (iuds), provide birth control for an extended period of time. iuds are the most effective type of reversible birth control for women who do not wish to become pregnant over the next couple years, have the lowest failure rate (winner, 2012), and in 2007, were used by more than 180 million women worldwide (darney, 2010). despite the high efficacy and low rates of side effects, women may decline placement of an iud due to fear of pain associated with placement. iuds may act as a barrier to women selecting this method of contraception. currently there is no consensus in the literature as to the most effective way to address analgesia surrounding iud insertion. in order to eliminate barriers to selecting the iud for contraception, improve the experience of women undergoing placement, and standardize local practices, investigators want to investigate analgesic options affecting patients' perception of pain during the various steps of iud insertion.

Eligibility criteria:
inclusion criteria: * over 18 years of age, * desires to undergo placement of a levonorgestrel containing intrauterine device exclusion criteria: * device manufacturer contraindications such as signs of genital infection, positive urine pregnancy test, abnormal vaginal bleeding, abnormal sized uterus that sounds \ 10cm, and all other contraindications to placement of a levonorgestrel containing iud. * patients with a history of drug abuse. * history of a prior iud * current use of medications for anxiety * also, a diagnosis of chronic pain.

Keywords: contraception iud levonorgestrel releasing intrauterine device lidocaine valium diazepam pain vas visual analog scale
how would the creation of a follow-up methodology in consultation improve the care of the epileptic patient?

Conditions: Epilepsy

Summary: the goal of this observationnal study is to identify the informative and educational needs of epilepsy patients to avoid interrupting the therapeutic pathway. the main question it aims to answer are : * identify the patient's expectations of a nurse specializing in epilepsy in the areas of information, predictive elements of good care and adaptation to their state of health * identify under-addressed or misunderstood themes * identify patient resources and interventions already in place * ensuring better continuity of care * improve the knowledge of patients and their relatives about the management of their pathology after a consultation with the neurologist (as part of their usual follow-up), the participants will be referred to a nurse for a semi-directive, individual interview, lasting 30 minutes and composed of open and closed questions. the announcement of the diagnosis, the quality of life or the factors contributing to the difficulties and their repercussions on a daily basis will be discussed during the interview.


Eligibility criteria:
inclusion criteria: * adult epileptic patients, over 18 years old * patients with focal or generalized epilepsy * patients affiliated or entitled to a social security scheme * patients who have received informed information about the study and who have co- signed, with the investigator, a non-objection to participation in the study * patients whose diagnosis has been made for at least 6 months exclusion criteria: * patients with intellectual disabilities * minors * untreated patients, in remission * patients without affiliation to a social security scheme * patients under guardianship or curatorship
early use of tacrolimus in hla-mismatched haploidentical allogeneic hematopoietic transplantation with post-transplant cyclophosphamide

Conditions: Hematologic Disease and Disorders; Hematopoietic Cell Transplant

Summary: to evalute the safety and efficacy in reducing cytokine release syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process


Eligibility criteria:
inclusion criteria: * availability of a 5/10-8/10 mismatched (hla-a, b, dr) haploidentical related donor with a negative hla cross-match in the host vs. graft direction and willing to provide peripheral blood stem cells * karnofsky status \>/= 70% * hematologic malignancy requiring allogeneic transplantation * first allogeneic transplant only. prior autologous transplant is allowed. exclusion criteria: * poor cardiac function: lvef \<40% * poor pulmonary function: fev1 and fvc \<50% predicted * poor liver function: bilirubin \>/= 3mg/dl (not due to hemolysis, gilbert's or primary malignancy) * poor renal function: creatinine \>/= 2mg/dl or creatinine clearance (calculated or measured creatinine clearance is permitted) \<40ml/min based on traditional cockcroft-gault formula * women of childbearing potential who currently are pregnant or who are not practicing adequate contraception * patients who have any debilitating medical or psychiatric illness that would preclude their giving informed consent or their receiving optimal treatment and follow up
evaluation of efficay & safety of galcanezumab in the prevention of episodic migraine- the evolve-2 study

Conditions: Migraine

Summary: the main purpose of this study is to evaluate the efficacy and safety of the study drug known as galcanezumab in participants with episodic migraine.


Eligibility criteria:
inclusion criteria: * have a diagnosis of migraine as defined by international headache society (ihs) international classification of headache disorders (ichd)-3 beta version (1.1 or 1.2) (ichd-3 2013), with a history of migraine headaches of at least 1 year prior to screening, migraine onset prior to age 50 and monthly frequency of 4-14 mhd. exclusion criteria: * are currently enrolled in or have participated within the last 30 days or within 5 half-lives (whichever is longer) in a clinical trial involving an investigational product. * current use or prior exposure to galcanezumab or another calcitonin gene-related peptide (cgrp) antibody. * known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins, or to galcanezumab. * history of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine) defined by ihs ichd-3 beta.

Keywords: prevention prophylaxis headache
response of haemodialysis patients to bnt162b2 mrna cov-19 vaccine

Conditions: COVID-19 Vaccines; Hemodialysis Complication

Summary: vaccination against sars-cov2 is a necessity for haemodialysis patients because difficulties to maintain a self-isolation (leading to a higher contamination than general population) and an increase of mortality in case of contamination (more than 20% of mortality in this population). however, vaccine efficiency is known to be decreased in haemodialysis patients. this lead critical the rapid description of immunogenicity of anti sars-cov2 vaccine in haemodialysis patients. the aim of this study is to describe the immunogenicity of the btn162b2 sars-cov2 vaccine in haemodialysis patients.


Eligibility criteria:
inclusion criteria: * medical prescription of btn162b2 mrna cov-19 vaccine * treatment by chronic (\>1 month) haemodialysis exclusion criteria: * non-recommended vaccination scheme * refusal to consent

Keywords: immunogenicity haemodialysis patients sars-cov2 vaccine
risk factors and biomarkers associated with recurrence after excision of primary pterygium

Conditions: Pterygium

Summary: this study looks at global gene expression in pterygium and found the derangement of matrix genes in particular to be a feature of pterygium. in the investigators opinion, it would be more beneficial to elicit changes in gene expression before the recurrence of pterygium and by developing a panel of biomarkers that are associated with pterygium recurrence; one would be able to predict the post surgical prognosis of patients after resection.biomarker levels will be compared to discover a biomarker panel for prediction of recurrence.

a comprehensive questionnaire will be used to evaluate the environmental, biological, physical and behavioral risk factors of associated with the recurrence after pterygium excision. slit lamp digital color photographs will be taken on primary and recurrent pterygium and pterygium will be graded in three levels of severity, based on relative transparency of pterygium tissue; grade 1 (transparent), grade 2 (intermediate), and grade 3 (opaque) to see whether the risk factors correlate to the morphology of the pterygium. tear samples will be collected before surgery using schirmers strip.proteins in tear samples will be analyzed using the itraq method. the transcriptional differences in pterygium and conjunctival tissue samples will be analyzed using western blot, qpcr and immunohistochemistry assays.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of primary and recurrence pterygium * must agree to participate in this study * must sign informed consent form exclusion criteria: * hepatitis * hiv/aids
hydrogel injection to assist endoscopic submucosal dissection

Conditions: Submucosal Tumor of Gastrointestinal Tract

Summary: the aim of the investigators' study is to evaluate the mucosa-elevating capacity and clinical safety of sodium alginate (sa) mixed with calcium lactate in assisting endoscopic submucosal dissection/endoscopic mucosal resection.

the study will evaluate the mucosa-elevating capacity and clinical safety of gut guarding gel (the sodium alginate (sa) mixed with calcium lactate) in assisting endoscopic submucosal dissection/endoscopic mucosal resection to treat early gastroenterological tumor and polyps. all participants in the study received endoscopic submucosal dissection with sodium alginate mixed with calcium lactate prior to endoscopic resection. the product is used in endoscopic submucosal dissection which is accomplished by steps listed as follows: lesion marking, submucosal injection, mucosal incision, submucosal dissection, then en-bloc resection. it's a new submucosal injection regimen, sodium alginate mixed with calcium lactate, which turned to calcium-alginate gel, we called it as "gut guarding gel". determine the rates of the delayed bleeding/perforation, postpolypectomy electrocoagulation syndrome, and the late tissue injury.

Eligibility criteria:
inclusion criteria: patients must meet all of the following inclusion criteria in order to be entered into the study: a. both genders of patients age 20 or older. b. superficial tumors or polyps found either in esophagus, stomach, or large intestine via endoscopic diagnosis. c. tumor or polyps ≧ 20 millimeters. d. superficial tumor or polyps found either in esophagus, stomach, or large intestine have never received any kind of endoscopic treatment. e. no evidence of depth of submucosal invasion or metastasis via endoscopy. exclusion criteria: if patients meet any of the following criteria they may not be entered into the study: a. patients suffering from other advanced malignant tumors. b. white blood cell\< 2000 μl or severe thrombocytopenia（platelet count \< 50,000 μl)，or blood coagulation abnormalities uncorrectable . c. patients taking anti- thrombocytopenia or anti-coagulation medicine, and medication cannot be stopped under physicians' consideration. d. main organs (heart, lung, liver, kidney) dysfunction who are not eligible for clinical trials under physicians' consideration. e. evidence of depth of submucosal invasion or metastasis via endoscopy. f. unable to follow-up by endoscopy. g. unwilling to sign informed consent. h. allergic to pharmaceutical excipients related to this medical device (calcium lactate or sodium alginate).

Keywords: sodium alginate calcium lactate gel
a clinical trial of b019 injection in patients with relapsed or refractory b-cell non-hodgkin's lymphoma.

Conditions: Relapsed or Refractory B Cell Non Hodgkin Lymphoma

Summary: the purpose of the study is to evaluate the safety、tolerability and preliminary efficacy of b019 in subjects with relapsed or refractory b-cell non-hodgkin's lymphoma.


Eligibility criteria:
inclusion criteria: 1. subjects who can fully understand this trial and voluntarily sign the informed consent form (icf) before any research-related procedures; 2. histologically confirmed b-cell non-hodgkin's lymphoma (b-nhl) with specified pathological subtypes; 3. histologically confirmed cd19 and/or cd22 positivity; 4. expected survival time exceeding 12 weeks; 5. ecog performance status 0-1 (ia) or 0-2 (ib); 6. at least one measurable lesion in two dimensions according to the lugano 2014 criteria; 7. bone marrow, liver, kidney, and cardiac-pulmonary functions meeting the specified requirements; 8 subjects who were evaluated by the researchers as tolerant to the collection of peripheral blood mononuclear cells (pbmc); 9 subjects who were evaluated by the researchers as having no contraindications for lymphodepleting chemotherapy. exclusion criteria: 1. primary central nervous system (cns) lymphoma; however, secondary cns lymphoma without clinical symptoms can be enrolled after being determined by the researchers； 2. use of the prescribed drugs or treatments within the specified time before the collection of pbmc; 3. prior allogeneic hematopoietic stem cell transplantation; 4. systemic intravenous infusion treatment or uncontrollable bacterial, fungal or viral infection within 2 weeks before signing the icf; 5. a history of deep vein thrombosis or pulmonary embolism or anticoagulant therapy within 6 months before signing the icf; 6. a clinically significant history of severe heart disease within 6 months before signing the icf; 7. terminal organ damage or autoimmune diseases requiring systemic immunosuppressive/systemic treatments within 2 years before signing the icf; or have graft-versus-host disease; 8. prescribed malignant tumors within 5 years before signing the icf; 9. intestinal obstruction caused by tumor compression or vascular compression requiring emergency treatment; gastrointestinal involvement with a risk of bleeding assessed by the researchers; 10. clinically significant cns diseases in the past or at the time of screening; 11. a history of severe allergic reactions to the drugs or excipients that were definitely needed in this study. or have a history of allergic reactions to tocilizumab; 12. any indwelling tubes or drainage tubes in the bodies, the use of dedicated central venous access catheters is permitted; 13. pregnant or breastfeeding women; or male or female subjects who are unwilling to use contraception from the time of signing the icf until 1 year after receiving b019 injection cell infusion or until car is detectable in peripheral blood.; 14. other circumstances that the researchers consider unsuitable for participating in this study.
mind matters: a high touch, low cost approach to improving mental health outcomes in patients with psoriatic diseases

Conditions: Arthritis, Psoriatic; Psoriasis

Summary: despite advances in effective psoriatic disease treatment, the disease still has a serious impact on mental health and well-being of millions of patients. up to 20.7% of patients report poor mental health, compared to 7.1% of the general population. mental health treatment involves a combination of medication and talk therapy to address such issues. however, there is increasing evidence that optimizing behaviors such as sleep, physical activity, stress, and nutrition are critical components in improving mental health too. numerous online health programs have evolved to help patients optimize such behaviors but very little exists for patients with psoriatic diseases. the "immune strength" 12 week program utilizes online electronic coaching (ecoaching) with weekly access to a wellness professional to provide a low-cost, high-touch, personalized intervention that patients can access 24/7. in conjunction with traditional clinical care, the goal of this program is to leverage the convenience, affordability, scalability and effectiveness of an online ecoaching program to improve key physical behaviors, thereby reducing the mental health burden experienced by psoriatic disease patients.


Eligibility criteria:
inclusion criteria: * patient of cleveland clinic * adults (=18 years of age) * diagnosis of psoriasis or psoriatic arthritis by a board certified physician. * phq9 score between 5 and 20 * computer and internet access * a valid email address * able to speak \& read english * able to understand \& sign informed consent exclusion criteria: * phq9 score \> 20 * history of major depressive disorder * currently receiving psychotherapy for major depressive disorder (mdd), anxiety or psychotic disorder * on a wait-list for psychotherapeutic treatment * received treatment for a severe psychiatric illness in the previous 6 months * demonstrate a notable suicidal risk at study visit

Keywords: psoriatic arthritis psoriasis mental health well being
a study of long-term rituximab (mabthera) maintenance therapy in participants with advanced follicular lymphoma

Conditions: Lymphoma, Follicular

Summary: this study will evaluate the efficacy, safety, and tolerability of long-term maintenance therapy with rituximab in participants with advanced follicular lymphoma who have had a positive response to first-line treatment with a rituximab-containing regimen. the anticipated time on study treatment is 2 years, and the target sample size is 124 individuals.


Eligibility criteria:
inclusion criteria: * adult participants greater than (\>) 18 years of age * histologically confirmed follicular lymphoma grade 1, 2, or 3a with lymph node biopsy within 4 months of induction treatment * no previous anti-lymphoma treatment before induction chemotherapy (first-line-treated participants only are eligible) * verified complete or partial remission after first-line induction therapy including rituximab exclusion criteria: * grade 3b follicular lymphoma * transformation to high-grade lymphoma (except to grade 3a) of previously existing follicular lymphoma * presence of central nervous system lymphoma * acquired immunodeficiency syndrome-related lymphoma * other primary malignancy (other than squamous cell cancer of the skin or in situ cancer of the cervix) for which the participant has not been disease-free for greater than or equal to (\>=) 5 years